Parametric Portfolio Associates LLC lifted its position in shares of Agilent Technologies, Inc. (NYSE:A) by 13.7% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 587,070 shares of the medical research company’s stock after purchasing an additional 70,690 shares during the quarter. Parametric Portfolio Associates LLC owned 0.18% of Agilent Technologies worth $34,819,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. BlackRock Inc. grew its stake in shares of Agilent Technologies by 1.2% during the 2nd quarter. BlackRock Inc. now owns 23,392,338 shares of the medical research company’s stock worth $1,387,400,000 after purchasing an additional 273,119 shares during the period. Vanguard Group Inc. grew its stake in shares of Agilent Technologies by 3.0% during the 2nd quarter. Vanguard Group Inc. now owns 22,093,669 shares of the medical research company’s stock worth $1,310,374,000 after purchasing an additional 637,698 shares during the period. FMR LLC grew its stake in shares of Agilent Technologies by 3.9% during the 1st quarter. FMR LLC now owns 21,588,407 shares of the medical research company’s stock worth $1,141,379,000 after purchasing an additional 803,993 shares during the period. State Street Corp grew its stake in shares of Agilent Technologies by 1.0% during the 1st quarter. State Street Corp now owns 14,457,425 shares of the medical research company’s stock worth $764,348,000 after purchasing an additional 147,518 shares during the period. Finally, JPMorgan Chase & Co. grew its stake in shares of Agilent Technologies by 45.2% during the 2nd quarter. JPMorgan Chase & Co. now owns 12,145,610 shares of the medical research company’s stock worth $720,358,000 after purchasing an additional 3,779,099 shares during the period.

In other Agilent Technologies news, CEO Michael R. Mcmullen sold 16,492 shares of the company’s stock in a transaction on Thursday, September 14th. The stock was sold at an average price of $65.33, for a total value of $1,077,422.36. Following the sale, the chief executive officer now owns 211,872 shares of the company’s stock, valued at $13,841,597.76. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Didier Hirsch sold 15,555 shares of the company’s stock in a transaction on Friday, September 15th. The shares were sold at an average price of $66.00, for a total value of $1,026,630.00. Following the completion of the sale, the chief financial officer now directly owns 178,557 shares in the company, valued at approximately $11,784,762. The disclosure for this sale can be found here. Insiders sold 170,720 shares of company stock worth $10,795,039 in the last three months.

COPYRIGHT VIOLATION NOTICE: “Parametric Portfolio Associates LLC Has $34.82 Million Stake in Agilent Technologies, Inc. (A)” was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The legal version of this story can be read at https://www.watchlistnews.com/parametric-portfolio-associates-llc-has-34-82-million-stake-in-agilent-technologies-inc-a/1598615.html.

A number of equities research analysts have recently commented on the stock. Bank of America Corporation reaffirmed an “equal weight” rating on shares of Agilent Technologies in a research note on Tuesday, August 15th. BidaskClub cut shares of Agilent Technologies from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Deutsche Bank AG set a $68.00 price target on shares of Agilent Technologies and gave the company a “buy” rating in a research note on Wednesday, August 16th. Morgan Stanley reissued an “overweight” rating on shares of Agilent Technologies in a research note on Wednesday, August 16th. Finally, Goldman Sachs Group, Inc. (The) reissued a “neutral” rating and issued a $68.00 price target on shares of Agilent Technologies in a research note on Tuesday. Four equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $64.38.

Agilent Technologies, Inc. (NYSE A) opened at 64.20 on Friday. The firm has a 50-day moving average price of $62.75 and a 200-day moving average price of $58.31. The stock has a market cap of $20.66 billion, a price-to-earnings ratio of 33.11 and a beta of 1.30. Agilent Technologies, Inc. has a one year low of $42.92 and a one year high of $66.45.

Agilent Technologies (NYSE:A) last posted its earnings results on Tuesday, August 15th. The medical research company reported $0.59 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.52 by $0.07. The company had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.09 billion. Agilent Technologies had a return on equity of 16.95% and a net margin of 14.36%. Agilent Technologies’s revenue was up 6.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.49 earnings per share. On average, equities analysts predict that Agilent Technologies, Inc. will post $2.32 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 25th. Shareholders of record on Tuesday, October 3rd will be issued a $0.132 dividend. This represents a $0.53 annualized dividend and a yield of 0.82%. The ex-dividend date of this dividend is Monday, October 2nd. Agilent Technologies’s dividend payout ratio (DPR) is 27.32%.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.

Want to see what other hedge funds are holding A? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agilent Technologies, Inc. (NYSE:A).

Institutional Ownership by Quarter for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.